Blanket Purchase Agreement V797D70102-VA797E17A0008

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Vanda Pharmaceuticals Inc. as a single award contract. The BPA has a ceiling value of $3,753,465.00 and a period of performance through September 5, 2026. The purpose of this BPA is to provide the Department of Veterans Affairs (VA) with the pharmaceutical product HETLIOZ (tasimelteon). HETLIOZ is used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency of the U.S. government, to Vanda Pharmaceuticals Inc. (Vanda) on October 26, 2022. The single-award BPA has a ceiling value of $3,069,780 and a period of performance through August 31, 2024. The BPA is for the procurement of Hetlioz (tasimelteon), a medication used to treat Non-24-Hour Sleep-Wake Disorder in blind adults and patients with Smith-Magenis Syndrome. Vanda is the manufacturer of...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency, to Sanofi-Aventis U.S. LLC, a foreign-owned for-profit organization, with no set-aside used. The single-award BPA has a ceiling value of $5,000,000.00 and a period of performance from July 1, 2024, to June 30, 2026. The BPA is for the procurement of TZIELD, a pharmaceutical product. As a BPA, this contract provides a streamlined mechanism for the agency to order and obtain TZIELD from the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center (NAC), a civilian agency, to Soleno Therapeutics Inc. The BPA has a ceiling value of $2,500,000.00 and a period of performance through May 19, 2026. The BPA is for the procurement of products and services described as "BPA FOR VYKAT", though the specific details of the required products and services are not provided. The contract does not utilize any set-asides and was awarded as a single-award...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to PTC Therapeutics, Inc. as the prime contractor. The BPA, valued at a ceiling of $12,500.00, is for the procurement of EMFLAZA, a medication. The BPA was awarded on March 9, 2024, with a period of performance ending on March 14, 2026. The contract was a single award, with no set-aside used. As a BPA, this contract provides a streamlined mechanism for the agency to order and...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to HRA Pharma America, Inc. as the prime contractor. The BPA has a period of performance from June 10, 2025 to June 9, 2026 and a ceiling value of $1,386,062.00. The BPA is for the procurement of the pharmaceutical products Lysodren and Metopirone. No set-asides were used for this single-award contract. The purpose of this BPA is to establish a contract vehicle through which the...

This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian federal agency, to Actelion Pharmaceuticals US, Inc., a large pharmaceutical manufacturer. The BPA has a ceiling value of $118,500,000 and a period of performance from August 2024 to August 2026, with an option year extending it to August 2027. The BPA is for the procurement of specialized pharmaceutical products, primarily focused on medications for the treatment of rare diseases and pulmonary...

This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...

The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Travere Therapeutics, Inc. for the procurement of cholbam and thiola from the Pharmaceuticals and Drugs Federal Supply Schedule. The single award BPA has a potential value of $25 million and a period of performance through September 14, 2021. The BPA utilizes Travere Therapeutics' position on the GSA Pharmaceuticals and Drugs Schedule to establish fixed pricing, terms, and conditions...

This Blanket Purchase Agreement (BPA) contract was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Travere Therapeutics, Inc., a biopharmaceutical company specializing in rare disease therapies. The $25 million BPA, effective from September 15, 2021 through September 14, 2026, is for the procurement of the pharmaceutical products Thiola (tiopronin) and Cholbam (cholic acid). These specialized medications are used to treat cystinuria and bile acid synthesis...